表紙
市場調查報告書

全球生命科學產業預測:2020年

Predictions for the Global Life Sciences Industry, 2020

出版商 Frost & Sullivan 商品編碼 926016
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
全球生命科學產業預測:2020年 Predictions for the Global Life Sciences Industry, 2020
出版日期: 2020年01月31日內容資訊: 英文 45 Pages
簡介

全球生命科學產業成長軌道受益於CRISPR-Cas9、微生物組、單細胞等的新技術組合,以及中國等市場的進入阻礙放寬、次世代治療法和伴隨式診斷相關規範框架的明確化。

本報告研究全球生命科學產業,分析彙整預測、對利害相關者的影響、矚目企業等情報。

摘要整理

生命科學:2020年預測

  • 預測1:癌症和罕見疾病新藥發現創新中加速採用的工智慧
  • 對利害相關者的主要影響
  • 主要矚目企業
  • 預測2:基於微生物組的癌症治療見證最密集的臨床PIPELINE資本流入
  • 對利害相關者的主要影響
  • 主要矚目企業
  • 預測3:連網智能的生物程序提升生物製造生產力
  • 對利害相關者的主要影響
  • 主要矚目企業
  • 預測4:基因組定序創製觸發日本精準醫療IVD
  • 對利害相關者的主要影響
  • 主要矚目企業
  • 預測5:監管市場中基於年金模式的Catapult基因治療的商業化
  • 對利害相關者的主要影響
  • 主要矚目企業

成長機會和企業行動

  • 生命科學企業策略要務

結論

附錄

關於Frost & Sullivan

目錄
Product Code: 9AB9/C3

2020 is Expected to be a Landmark Year for New Digital-tech Adoption, and Sustainable Pricing Models will Encourage Stronger, New Product Pipelines

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics.

A common denominator of growth achieved thus far has been developments in the digital arena including, but not limited to, operationalizing Artificial Intelligence platforms, Internet of Medical Things, Real World Evidence, and Blockchain. As use cases and applications in life sciences of the aforementioned technologies increase, its impact will be realized in the coming years. Digital continuity will provide the framework and transparency required throughout the clinical development lifecycle. This study explores specific technologies that are expected to have the largest impact across the drug lifecycle.

While new technologies and platforms are driving the development of novel therapies, the genesis of most therapies has been in academic institutes and research centers. Therefore, economical manufacturing scale-up remains a critical impediment in advancing these therapies from the lab to clinics. Moreover, as pharma companies face pressure from all directions with the risk of negatively- affected profitability, companies are exploring unconventional solutions to introduce optimization and sustainability of profits. One such measure is taking biomanufacturing to next-generation smart facilities that offer greater connectivity, continuity, reproducibility, and efficiency of operations; 2019 witnessed a string of such biopharmaceutical manufacturing facility expansions. This study explores more specific tangents of connected and intelligent bioprocessing and highlights the key companies that are enabling this change.

Multiple approvals and commercial launches clubbed with improvements in manufacturing capability have paved way for next generation and cell and gene therapies to become mainstream. While biopharma investment continues unabated in this segment due to high clinical potential, sustainable reimbursement models will be the key to unlocking true commercial potential. This research service provides insights into the reimbursement models which will change the course of business strategies for pharma companies and associated stakeholders and ensure sustainable growth in the segment.

Lastly, the study highlights the convergence of pharmaceuticals, new diagnostic technologies, and unavoidable need for companion diagnostics, which has been enabled by the regulatory and commercial evolution in the global life sciences industry. With a large number of innovations in diagnostics coming from global IVD players, local companies in the APAC region are using multilateral collaborations to facilitate early introduction of innovations in local markets as well as shaping portfolio choices to bridge gaps in high growth but under-served markets.

Table of Contents

Executive Summary

  • Scope
  • Key Questions this Study will Answer
  • Pharma and Biotech
  • Segment Snapshot-Pharma and Biotech
  • IVD and Research Tools
  • Segment Snapshot-IVD and Research Tools

Life Sciences-Predictions for 2020

  • Prediction 1-Artificial Intelligence to Witness Accelerated Adoption in Drug Discovery Innovation in Cancer and Rare Diseases
  • Key Implications for Stakeholders
  • Key Companies to Watch in 2020
  • Prediction 2-Microbiome-based Cancer Therapy to Witness Densest Clinical Pipeline and Capital Influx
  • Key Implications for Stakeholders
  • Key Companies to Watch in 2020
  • Prediction 3-Connected and Intelligent Bioprocessing to Improve Biologic Manufacturing Productivity
  • Key Implications for Stakeholders
  • Key Companies to Watch in 2020
  • Prediction 4-Genome Sequencing Initiatives to Trigger Precision Medicine IVD in Japan
  • Key Implications for Stakeholders
  • Key Companies to Watch in 2020
  • Prediction 5-Annuity-based Model to Catapult Gene Therapy Commercialization in Regulated Markets
  • Key Implications for Stakeholders
  • Key Companies to Watch in 2020

Growth Opportunities and Companies to Action

  • Strategic Imperatives for Life Sciences Companies

Last Word

  • Impact of Technology on LS Stakeholders
  • Legal Disclaimer

Appendix

  • Geographical Trends
  • Abbreviations
  • Abbreviations (continued)
  • List of Exhibits

The Frost & Sullivan Story

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360º Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy